73 results about "Chronic inflammatory disease" patented technology

The invention discloses a frozen gel microneedle as well as a preparation method and application thereof, the preparation method comprises the following steps: (1) adding PBS (Phosphate Buffer Solution) into a brown bottle filled with an initiator LAP, and heating and stirring in a water bath at 40-50 DEG C for 15 minutes to obtain an initiator standard solution; (2) adding the initiator standard solution obtained in the step (1) into a brown glass bottle with HAMA, and stirring at room temperature in a dark place for 1 hour to obtain a photo-crosslinked HAMA hydrogel solution; (3) preparing a complete porous gel microneedle mold needle tip loaded with a gene therapy vector; (5) preparing a microneedle mold substrate; (6) freezing the microneedle mold with the formed needle tip and substrate to obtain a frozen gel microneedle array; and (7) demolding the frozen gel microneedle array to obtain the frozen gel microneedle. The obtained microneedle can be used for long-term collaborative treatment of chronic inflammatory diseases through percutaneous delivery of anti-inflammatory genes coded by CeNPs and rAAV2.

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More specifically, the present invention provides particles comprising MOFs, optionally at least one targeting moiety, and at least one short-lived radionuclide; compositions comprising the particles; the particles or compositions for use as imaging agents; the particles or compositions for use in methods for diagnosing proliferative diseases; the particles or compositions for use in methods for diagnosing chronic inflammatory diseases; and kits comprising particles comprising MOFs, optionally a targeting moiety, and a short-lived radionuclide cation.

The invention belongs to the field of biomedical materials, and discloses a preparation method and application of a mesoporous polydopamine nano preparation loaded with ultra-small nano enzyme. The nano preparation takes mesoporous polydopamine nanoparticles as a carrier skeleton and is combined with ultra-small nano enzyme through an in-situ reaction: the mesoporous polydopamine nanoparticles can efficiently carry drugs and accurately deliver the drugs to inflammatory tissues such as psoriasis, gout, colitis and the like by virtue of a modified targeting ligand by virtue of high specific surface area, biocompatibility and modifiability; the ultra-small nano enzyme has catalytic activity of catalase and the like, and can remove active oxygen and relieve oxidative stress. The two components are combined to achieve a synergistic effect, so that the catalytic efficiency of the enzyme is improved by virtue of the characteristics of the carrier, the high activity of the enzyme under different conditions is maintained by virtue of the stability of the carrier, and the platform can synchronously realize targeted delivery, enzymatic treatment and drug controlled release, and has a wide application prospect in the fields of inflammatory disease intervention and wound repair. And an efficient, accurate and low-toxicity universal treatment strategy is provided for chronic inflammatory diseases.

The present invention relates to a novel anti-CD40 antibody and use thereof and, more specifically, to a novel anti-CD40 antibody and use thereof, wherein the antibody comprises a complementarity determining region of a specific sequence and exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling. The novel anti-CD40 antibody of the present invention exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling, and thus can be widely used as a preparation for preventing or treating various diseases, such as autoimmune diseases and chronic inflammatory diseases, and as a preparation for inhibiting immune rejection at the time of transplantation.

The invention discloses a preparation method and application of bioactive lipid and lipid nanoparticles thereof. The bioactive lipid molecule is formed by bonding long-chain fatty acid (LCFA) with different chain lengths with two functional small molecules, namely phenylboronic acid pinacol ester (PBAP) and Tempol (Tpl) respectively, so that two types of lipid molecules, namely PBAP-LCFA and Tpl-LCFA, with anti-inflammatory activity are constructed. The lipids are used as functional components, and the anti-inflammatory lipid nanoparticles with good biocompatibility, including PLP, TLP and TPLP, can be prepared through a film dispersion method. The lipidoid and the lipid nanoparticles are simple and convenient in preparation process, controllable in structure and function and easy for large-scale production, and have treatment potential in various acute and chronic inflammatory diseases. In an animal model, the lipid nanoparticles have remarkable curative effects on acute peritonitis, acute lung injury, acute hepatic failure, asthma and other diseases. Besides, the lipid bilayer structure of the TPLP can efficiently entrap hydrophilic / hydrophobic drugs, can synergistically deliver treatment drugs while exerting the anti-inflammatory effect of the TPLP, and realizes a synergistic combined treatment strategy for chronic lung inflammation and other diseases.

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that specifically bind to pathologic T-cells, and methods of use in the treatment of autoimmune disease, transplant rejection, T cell malignancies, and chronic inflammatory disease.

The application discloses application of Bifidobacterium longum exopolysaccharide or a co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and probiotics in improving inflammation. The application finds that the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can inhibit LPS-induced TLR4 / NfkB (P65) signal path activation, inhibit the polarization of macrophages from M0 to M1, thereby inhibiting inflammatory reactions, and the inhibiting effect of the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus is more obvious. Therefore, the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can be used for preparing drugs for inhibiting inflammatory reactions, and are helpful to the treatment of immune and chronic inflammatory diseases and the development of related drugs.

The present disclosure relates to smallpox vaccines and stem cells for treating diseases. Described herein are methods and compositions for treating an inflammatory disease or an infectious disease in a subject in need thereof by administering a poxvirus and a stem cell to the subject, wherein the disease is not a cancer. For example, the disease can be a chronic inflammatory disease (e.g., an autoimmune disease).

A protein comprising an amino acid sequence according to SEQ ID NO: 1, wherein the amino acid in position 4 of SEQ ID NO: 1 is selected from the group consisting of N, S, R, T and I, preferably consisting of N, S and R and wherein the amino acid in position 5 of SEQ ID NO: 1 is selected from the group consisting of R, V, L, F, M, I, H, S, T, A, P and G, with the proviso that the amino acid sequence is not SEQ ID NO: 24.

The application discloses a carbonyl heterocyclic compound and application thereof. The application provides a carbonyl heterocyclic compound as shown in formula II or a pharmaceutically acceptable salt thereof; the compound can be used as a compound with a targeted lipoamide synthetase C-like protein 2 path; and the compound can be used for treating various conditions, including infectious diseases, autoimmune diseases, diabetes and chronic inflammatory diseases.

The present invention discloses the use of neratinib or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for preventing or treating atherosclerotic disease. Atherosclerotic disease is a chronic inflammatory disease of the vascular lining. Low-density lipoprotein and inflammatory cells accumulate in damaged areas of the vascular lining, gradually forming lipid streaks that further develop into lipid plaques, i.e., atherosclerosis. Neratinib has the effect of inhibiting inflammatory responses and is therefore useful in the preparation of a medicament for preventing or treating atherosclerotic disease.

The invention relates to pharmaceutics, and more particularly to gastroenterology, and can be used for the prophylaxis or treatment of inflammatory diseases of the gastrointestinal tract. What is described is the use of trimebutine maleate to achieve a maximum change in the level of the proinflammatory cytokines IL-1, IL-6, TNF-α, NF-κB and the anti-inflammatory cytokine IL-10 in the gastrointestinal tract for the prophylaxis or treatment of acute and chronic inflammatory diseases of the gastrointestinal tract.

The present invention relates to an inhibitor of CD74 protein activity or expression, for the therapeutic use thereof in the prevention and / or treatment of chronic inflammatory diseases including: chronic inflammatory rheumatisms, chronic inflammatory dermatoses, chronic inflammatory bowel diseases and chronic inflammatory neurological diseases. In another embodiment, the invention relates to an isolated anti-CD74 antibody or fragment thereof, comprising six CDRs having the sequences SEQ ID NO. 3, 4, 5, 11, 12, and 13.

The invention provides an oral liquid based on algal oil-curcumin synergistic anti-inflammation and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The oral liquid comprises the following raw materials: an anti-inflammatory agent (consisting of algae oil and curcumin), a traditional Chinese medicine extract (consisting of a herba houttuyniae extract and an Indian kalimeris herb extract), phospholipid, fructo-oligosaccharide, an antioxidant, a stabilizer (consisting of Arabic gum and hydroxypropyl-beta-cyclodextrin) and a flavoring agent. Experimental results show that the anti-inflammatory oral liquid is high in stability, and the content of inflammatory factors in mice with LPS-induced chronic inflammation can be remarkably reduced. The oral liquid can relieve chronic inflammation symptoms by regulating immune cell functions, blocking inflammation signal channels and other multi-target mechanisms, is high in safety after being used for a long time, does not have obvious adverse reaction, and provides a new choice for clinical treatment of chronic inflammatory diseases.

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

The invention provides identification and preparation of a small open reading frame coding peptide (SEP) and application of the SEPs in inflammation regulation and control, belongs to the technical field of biomedical polypeptides, and particularly relates to enrichment of SEPs in an animal infection model sample, mass spectrometry and sample preparation as well as application of the SEPs in treatment of excessive inflammatory response. The SEPs screened in the invention have the advantages of small molecular weight, low production cost, good anti-inflammatory activity, and good anti-inflammatory treatment effect on an LPS-induced RAW264.7 cell inflammation model. The compound can be used for preparing a preparation for preventing or treating inflammatory infectious diseases, and inflammations include but not limited to acute and chronic inflammatory diseases caused by bacteria, immunity, drugs and the like.

The present invention relates to interleukin-2 variants, to pharmaceutical compositions comprising said interleukin-2 variants, in a pharmaceutically acceptable carrier, and to their implementation in the prevention or treatment of cancer, or in the prevention or treatment of a disease selected from the group consisting of acute or chronic inflammatory diseases, allergic diseases, autoimmune diseases, graft-versus-host disease and graft rejection.

The present invention relates to MOFs for use in imaging and as radiolabeled tracers. More particularly, the invention provides a particle comprising a MOF, optionally at least one targeting moiety and at least one short-lived radionuclide; a composition comprising said particle; said particle or composition for use as an imaging agent; said particle or composition for use in a method for the diagnosis of a proliferative disease; said particle or composition for use in a method for the diagnosis of a chronic inflammatory disease; and a kit comprising a particle comprising a MOF, an optional targeting moiety, and a short-lived radionuclide cation.

The present invention relates to a novel antagonistic anti-CD40 humanized antibody and, more specifically, to a novel humanized antibody specifically binding to CD40, which, by comprising a complementarity-determining region of a specific sequence, exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling. The novel anti-CD40 humanized antibody of the present invention exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling, and thus can be widely used as a preparation for preventing or treating various diseases, such as autoimmune diseases and chronic inflammatory diseases, and as a preparation for suppressing immune rejection upon transplantation.

The invention relates to negative functional modulators of at least one variant of the non-erythrogenic erythropoietin (V-EPO) and pharmaceutical compositions or kits containing them. Such functional negative modulators of V-EPO may be a mono- or multi-specific antibody anti-EV3, anti-EV4, anti-EV1-4, anti-EV1-5, anti-EV1-1, or EV2-1, or anti-Epo receptor (EpoR) anti-EPHB4, anti-CSF2RB, an antisense oligonucleotide, DNA decoy, RNA decoy, a ribozyme, an antagomiR, a shRNA, LNA or siRNA.Several uses of these functional modulators are described, which have been advantageously employed as a medicament and for the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing organ or tissue transplantation.The invention also describes variants of EPO for use in the diagnosis and in the treatment of an oncological pathology, a proliferative pathology, chronic inflammatory diseases on an autoimmune and non-autoimmune basis, of neurodegenerative diseases, and in the treatment of patients undergoing an organ or tissue transplantation and as a diagnostic agent.According to another aspect, a monoclonal antibody to at least one of the variants of the erythropoietin is described.According to yet another aspect, the use of at least one alternative splicing variant of non-erythrogenic EPO and the measurement thereof at tissue and / or systemic level is described, as well as the study of the methylation status of the promoters of the genes involved in the EPO signalling pathway (by way of example EPO, EPOR, EPHB4, CSF2RB), as diagnostic, prognostic and predictive markers of an oncological pathology, a proliferative pathology, neurodegenerative or inflammatory pathology.

The application discloses a 1-aryl-5-pyrazolone compound and a pharmaceutical composition and application thereof. The compound has a structure selected from any one of the following structures, and also comprises a tautomer, a pharmaceutically acceptable salt or a mixture thereof: the compound can effectively inhibit COX-2 and effectively scavenge free radicals at a micromolar concentration level, can reduce cardiovascular and digestive tract side effects caused by NSAID-induced free radical production, and can also play a better treatment effect on chronic inflammatory diseases with pain through the synergistic effect of antioxidation stress and anti-inflammatory analgesia.

Novel antibody molecules are described that specifically bind to TNFR2 on target cells and thereby agonize TNFR2 without blocking the binding of the ligand TNF-α to TNFR2. Also described are the uses of such antibody molecules in medicine, particularly in the treatment of cancer or chronic inflammatory diseases.

Provided are neutrophils and monocytes having unique combinations of cell surface markers capable of enhancing TRAMlo neutrophil or monocyte subsets, or capable of reprogramming neutrophils and monocytes into TRAM deficient neutrophils and monocytes, including methods of isolating the neutrophils and monocytes for use in treating chronic inflammatory diseases. The enhanced or reprogramed neutrophils may express surface markers comprising CD177lo and at least one of Dectin2 (Clec4n)lo, EHD1lo, CD84hi, Ly6E / Ly6Ahi, CD200Rhi, CD24hi, CD49Dlo, or a combination thereof, and the enhanced or reprogrammed monocytes may express surface markers comprising CD14+, CD16+, and at least one of CD24hi, CD200Rhi, or CD84hi.

The present application relates to a novel anti-CD40 antibody and use thereof, and more particularly, to a novel anti-CD40 antibody comprising a complementarity determining region of a specific sequence, which exhibits an excellent antagonistic effect by blocking CD40-CD40L signal transduction, and use thereof. The novel anti-CD40 antibody of the present application exhibits an excellent antagonistic effect by blocking CD40-CD40L signal transduction, and thus can be widely used as a preparation for preventing or treating various diseases such as autoimmune diseases, chronic inflammatory diseases, etc., and a preparation for inhibiting immune rejection at the time of transplantation.

The present invention relates to a novel compound represented by Formula 1, functioning as a sphingosine-1-phosphate receptor agonist useful for treating autoimmune disorders, a preparation method therefor, a pharmaceutical composition containing the same as an active ingredient, and a use. The compound according to the present invention has an effect in extensive autoimmune diseases and chronic inflammatory diseases, including relapsing-remitting multiple sclerosis, and can also be used for treating or preventing immunoregulatory disorders.

The present invention relates to methods of producing compounds of interest in a recombinant microorganism. In particular, the present invention relates to using a recombinant microorganism comprising a heterologous nucleic acid encoding one or more mycosporine-like amino acid (MAA) biosynthetic enzymes (e.g., MysH) to produce compounds of interest. Compositions comprising compounds produced using such methods are also provided herein. The present disclosure also provides methods of preventing sunburn, cancer, and chronic inflammatory diseases by administering such compositions to subjects in need thereof.

The invention belongs to the technical field of nutrition fortifiers, and particularly relates to a nutrition fortifier containing kelp extract and a preparation method of the nutrition fortifier. The nutrition enhancer containing the kelp extract comprises the following components in parts by mass: 20-30 parts of the kelp extract, 50-60 parts of soybean protein powder, 5-15 parts of oat powder, 1-10 parts of inulin, 1-10 parts of sea cucumber powder and 1-5 parts of an undaria pinnatifida extract. The kelp extract is subjected to directional fermentation treatment by adopting a specific probiotic strain, so that the content and biological activity of fucoidin in the kelp extract are remarkably improved; meanwhile, a multi-level nutrition collaboration system is constructed; especially for chronic inflammatory diseases such as tumors, arthritis and psoriasis, the nutrition enhancer provides a safe and long-acting diet intervention scheme for specific people through anti-inflammatory and anti-angiogenesis dual-path effects, and has important clinical auxiliary application value.

The present disclosure relates to use of Atovaquone for treating and preventing acute and chronic inflammatory diseases in a mammal. The acute and chronic inflammatory diseases comprise mast cell-mediated inflammatory diseases.

The present application relates to pyrazole derivatives as inhibitors of the PD-1 / PD-L1 interaction. The applicants have designed compounds of general formula (I) wherein R ', R2, y3, R3, R4, R5, R6 and R7 are as defined herein, which are effective in blocking PD-1 / PD-L1 interactions to restore an anti-tumor immune response in a subject and eradicate any tumors in which dormant tumor cells and PD-L1 participate in immune escape. The inventor verifies that these compounds block the PD-1 / PD-L1 interaction by performing physical and chemical tests (MST, NanoDSF) and in vitro biological tests (FRET assay, Pralomig block assay, T cell assay). These compounds have affinity (Kd) in the order of pM, which Kd is higher than the Kd of the antibody Atezumab used in clinical use, and have IC50 comparable to or higher than that observed using Atezumab. Therefore, the invention also relates to a pharmaceutical composition containing the compound and application of the pharmaceutical composition in treatment of PD-1-PD-L1 interaction related diseases (cancers, chronic inflammatory diseases, neurological diseases and chronic infections).

This invention discloses a plasma-activated silver nanogel, its preparation method, and its application. The preparation method includes the following steps: S1, mixing silver nanoparticles with agarose solution, heating and reacting, and then allowing it to stand until it becomes a gel; S2, immersing the gel obtained in S1 in physiological saline; S3, subjecting the gel treated in S2 to plasma treatment to obtain the plasma-activated silver nanogel. The method of this invention locks the active particles in the gel before applying it to the skin surface, avoiding direct or close-range contact between the plasma generator and the skin, thus preventing skin burns and ensuring safety. Simultaneously, it synergistically enhances the effects of silver ions and ClO₂. ‑ It has a dual antibacterial mechanism, which relieves redness, swelling, and thickened scales, accelerates the resolution of inflammation, regulates the immune response, and relieves symptoms of chronic inflammatory diseases (such as psoriasis).